The coronavirus pandemic has highlighted not only the importance of vaccines and infectious disease drugs, but also their potential limitations.&nbsp;While vaccines for COVID-19 saved <a href="https://cbsnews.com/news/covid-19-vaccine-saved-nearly-20-million-lives-in-a-year-study-says/">20 million</a> lives in their first year alone, for instance, newer forms of the coronavirus, like omicron, can more easily elude the protection from infection and mild disease the shots offer. Adapting vaccines quickly enough to keep up with newer variants has proven a difficult feat, as has predicting which versions of the virus might need to be countered next.&nbsp;<a href="https://www.biopharmadive.com/news/flagship-launch-apriori-bio-virus-variants/626989/">Read more</a>

BioPharma Dive: Moderna founder launches Apriori with $50M to stay ahead of virus variants